November 18, 2026
Health news, explained with evidence
LIVE

Blood Pressure Drug May Help Reduce Cardiac Iron Overload in Thalassemia Patients

❤️ Conditions & Care 2 min read 👁 5

A meta-analysis of seven randomized controlled trials suggests that adding amlodipine to standard iron chelation therapy may significantly lower heart and systemic iron levels in patients with transfusion-dependent thalassemia.

❤️Conditions & Care

Key points

  • Combining amlodipine with standard iron chelation significantly reduced serum ferritin and heart iron levels at 6 and 12 months.
  • Myocardial T2* MRI measurements improved significantly after 12 months of combination therapy.
  • The findings are limited by small trial sizes and small overall study counts, requiring confirmation in larger trials.

Adding the calcium channel blocker amlodipine to standard iron chelation therapy may help reduce iron accumulation in the heart and bloodstream among patients with transfusion-dependent thalassemia, according to a systematic review and meta-analysis conducted by researchers from institutions in Egypt and Saudi Arabia.

Key Trial Findings

The research team analyzed data from seven randomized controlled trials published between 2013 and 2022, with sample sizes ranging from 15 to 64 participants. At six months, patients receiving adjunctive amlodipine alongside standard chelation therapy experienced significant reductions in serum ferritin levels and myocardial iron concentration compared to control groups. By 12 months, the combined regimen maintained significant decreases in heart iron burden and serum ferritin, while also showing significant improvements in myocardial T2* scan measurements. No significant differences were observed in liver iron concentration or left ventricular ejection fraction at either interval.

Clinical Significance and Limitations

Excessive iron accumulation, particularly cardiac siderosis, represents a primary cause of illness and mortality in individuals requiring chronic blood transfusions. Although these results indicate that amlodipine could potentially support existing chelation protocols to protect cardiac tissue, the authors emphasized that the evidence remains preliminary. The analysis was constrained by a small number of eligible trials, modest sample sizes, and methodological variation across the evaluated studies.

What to know: Amlodipine is an established medication widely prescribed for high blood pressure, but its role in treating iron overload is still under clinical evaluation. Individuals managing thalassemia should always consult their hematologist or primary physician before making any changes to their treatment regimen.

Source Nature Health Sciences — nature.com/articles/s41598-026-70365-0 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.